Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Leqvio Market Expected to Grow Between 2025 And 2029?
The scale of the leqvio market has expanded by XX (HCAGR) in the last few years. It’s projected to surge from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. This growth during the historic phase can be associated with several factors like the surge in funding for RNA-based drug creation, heightened expenditure on cholesterol control drugs, escalation in R&D and medicine development investments, improved awareness in healthcare, and the growing requirement for specialized medicines.
What Growth Rate Is Anticipated for the Leqvio Market in the Coming Years?
The market size of leqvio is anticipated to witness an XX (FCAGR) surge in the following years, escalating to a value of $XX million by 2029, with a compound annual growth rate (CAGR) of XX%. The predicted growth during the forecast period could be due to the increasing global instances of cardiovascular diseases, heightened awareness about the potency of PCSK9 inhibitors, a rise in high cholesterol cases, an ageing population, and expansion of biologic drugs. Notable trends in the forecast period encompass an escalating demand for enhanced hypercholesterolemia treatments, broader implications resulting from continued research, ongoing sanctioning from regulatory agencies like the FDA, advancements in biopharmaceutical research, and progressive drug development.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp
Who Are the Leading Companies in the Leqvio Market?
Major companies operating in the leqvio market include Novartis AG
What Are the Key Drivers of the Leqvio Market?
Growth within the Leqvio market is being spurred on by a rise in instances of cardiovascular diseases. Cardiovascular complications, which typically comprise heart-caused issues such as strokes, heart attacks, and high blood pressure, impact the blood vessels and heart. Several factors, such as an unhealthy diet, physical inactivity, ageing, diabetes, and high alcohol consumption contribute to the onset of these diseases. Leqvio aids in lowering LDL levels and reducing the risk of cardiovascular events by blocking the PCSK9 protein, which in turn boosts the liver’s capacity to clear LDL cholesterol from the bloodstream. To illustrate, data from the British Heart Foundation released in September 2024 confirms that heart and circulatory diseases affect around 7.6 million people in the UK, inclusive of close to 4 million males and about 3.6 million females. These diseases account for approximately 27% of all deaths in the UK, equating to an annual death toll of over 170,000, or an average of 480 deaths daily. This figures to one death every three minutes. Therefore, the escalating prevalence of cardiovascular diseases is fuelling the expansion of the Leqvio market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=20143&type=smp
What Are the Key Market Segments in the Leqvio Industry?
The leqvio market covered in this report is segmented –
1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors
2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia
3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions
4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers
What Are the Latest Trends in the Leqvio Market?
The primary trend in the leqvio market revolves around the development of advanced injectable prescription drugs aimed at offering durable treatments that enhance patient compliance and results. These injectable prescription drugs, which aim to control high cholesterol levels and mitigate cardiovascular risks, are typically administered at consistent intervals to maintain their therapeutic influence. As an example, in July 2023, Novartis, a pharmaceutical organization based in Switzerland, was granted approval from the US Food and Drug Administration (FDA) for a label update for Leqvio (inclisiran). This approval permitted Leqvio’s use at earlier stages for patients with elevated LDL-C levels and a heightened risk of cardiac disease, in combination with diet and statin therapy. Administered twice a year following two initial doses, it leads to a reduction in LDL-C levels by up to 52% and proves effective for patients who can’t achieve their LDL-C goals despite undergoing statin therapy. The VictORION clinical trial program validated the safety and effectiveness encapsulated in the label update.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report
What Are the Key Regional Markets in the Leqvio Industry?
North America was the largest region in the leqvio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20143
This Report Delivers Insight On:
1. How big is the leqvio market, and how is it changing globally?
2. Who are the major companies in the leqvio market, and how are they performing?
3. What are the key opportunities and risks in the leqvio market right now?
4. Which products or customer segments are growing the most in the leqvio market?
5. What factors are helping or slowing down the growth of the leqvio market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model